Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Erratum to 'Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma' [Eur J Cancer 108 (February 2019) 33-40].

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L.

Eur J Cancer. 2019 Sep;119:200-201. doi: 10.1016/j.ejca.2019.04.012. Epub 2019 Jul 11. No abstract available.

PMID:
31301937
2.

Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.

Verbiest A, Renders I, Caruso S, Couchy G, Job S, Laenen A, Verkarre V, Rioux-Leclercq N, Schöffski P, Vano Y, Elaidi RT, Lerut E, Albersen M, Oudard S, Fridman WH, Sautès-Fridman C, Albigès L, Wozniak A, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2019 Oct;17(5):e981-e994. doi: 10.1016/j.clgc.2019.05.009. Epub 2019 May 25.

PMID:
31229459
3.

Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth.

Roumenina LT, Daugan MV, Noé R, Petitprez F, Vano YA, Sanchez-Salas R, Becht E, Meilleroux J, Clec'h BL, Giraldo NA, Merle NS, Sun CM, Verkarre V, Validire P, Selves J, Lacroix L, Delfour O, Vandenberghe I, Thuilliez C, Keddani S, Sakhi IB, Barret E, Ferré P, Corvaïa N, Passioukov A, Chetaille E, Botto M, de Reynies A, Oudard SM, Mejean A, Cathelineau X, Sautès-Fridman C, Fridman WH.

Cancer Immunol Res. 2019 Jul;7(7):1091-1105. doi: 10.1158/2326-6066.CIR-18-0891. Epub 2019 Jun 4.

PMID:
31164356
4.

[Treatment of metastatic prostate cancer: what recent progress?]

Oudard S, Velev M, Belhadj Y, Vano Y, Thibault C.

Rev Prat. 2018 Sep;68(7):707-712. French. No abstract available.

PMID:
30869315
5.

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L.

Eur J Cancer. 2019 Feb;108:33-40. doi: 10.1016/j.ejca.2018.11.031. Epub 2019 Jan 5. Erratum in: Eur J Cancer. 2019 Sep;119:200-201.

PMID:
30616146
6.

Immunothérapie des cancers du rein.

Vano YA, Simonaggio A, Thibault C, Oudard S.

Bull Cancer. 2018 Dec;105 Suppl 1:S24-S34. doi: 10.1016/S0007-4551(18)30387-4. Review. French.

PMID:
30595195
7.

The clinical role of the TME in solid cancer.

Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH, Sautès-Fridman C.

Br J Cancer. 2019 Jan;120(1):45-53. doi: 10.1038/s41416-018-0327-z. Epub 2018 Nov 9. Review.

8.

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges.

Fournier L, Bellucci A, Vano Y, Bouaboula M, Thibault C, Elaidi R, Oudard S, Cuenod C.

Kidney Cancer. 2017 Nov 27;1(2):107-114. doi: 10.3233/KCA-170011. Review.

9.

Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.

Thibault C, Vano Y, Soulat G, Mirabel M.

Eur Heart J. 2018 Oct 7;39(38):3553. doi: 10.1093/eurheartj/ehy485. No abstract available.

PMID:
30107497
10.

Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients.

Vano YA, Oudard S, By MA, Têtu P, Thibault C, Aboudagga H, Scotté F, Elaidi R.

PLoS One. 2018 Apr 6;13(4):e0195042. doi: 10.1371/journal.pone.0195042. eCollection 2018.

11.

Immune-based identification of cancer patients at high risk of progression.

Vano YA, Petitprez F, Giraldo NA, Fridman WH, Sautès-Fridman C.

Curr Opin Immunol. 2018 Apr;51:97-102. doi: 10.1016/j.coi.2018.03.005. Epub 2018 Mar 16. Review.

PMID:
29554496
12.

[Tim-3: a novel biomarker and therapeutic target in oncology].

Granier C, Gey A, Dariane C, Mejean A, Timsit MO, Blanc C, Verkarre V, Radulescu C, Fabre E, Vano Y, Oudard S, Badoual C, Tartour É.

Med Sci (Paris). 2018 Mar;34(3):231-237. doi: 10.1051/medsci/20183403011. Epub 2018 Mar 16. Review. French.

13.

Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies.

Petitprez F, Vano YA, Becht E, Giraldo NA, de Reyniès A, Sautès-Fridman C, Fridman WH.

Cancer Immunol Immunother. 2018 Jun;67(6):981-988. doi: 10.1007/s00262-017-2058-z. Epub 2017 Sep 7. Review.

PMID:
28884365
14.

PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer.

Petitprez F, Fossati N, Vano Y, Freschi M, Becht E, Lucianò R, Calderaro J, Guédet T, Lacroix L, Rancoita PMV, Montorsi F, Fridman WH, Sautès-Fridman C, Briganti A, Doglioni C, Bellone M.

Eur Urol Focus. 2019 Mar;5(2):192-196. doi: 10.1016/j.euf.2017.05.013. Epub 2017 Jun 21.

PMID:
28753812
15.

Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice.

Casuscelli J, Vano YA, Fridman WH, Hsieh JJ.

Kidney Cancer. 2017 Jul 26;1(1):3-13. doi: 10.3233/KCA-170008. Review.

16.

[French national survey on incoming phone calls in oncology departments].

Joly F, Guillot A, Vano YA, Spaeth D, Topart D, Roffet P, El Amarti R, Hasbini A, Fléchon A.

Bull Cancer. 2017 Jun;104(6):565-573. doi: 10.1016/j.bulcan.2017.02.008. Epub 2017 Apr 6. French.

PMID:
28391984
17.

Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.

Clément-Zhao A, Auvray M, Aboudagga H, Blanc-Durand F, Angelergues A, Vano YA, Mercier F, El Awadly N, Verret B, Thibault C, Oudard S.

BJU Int. 2018 Feb;121(2):203-208. doi: 10.1111/bju.13855. Epub 2017 Apr 27.

18.

Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma.

Auclin E, Bourillon C, De Maio E, By MA, Seddik S, Fournier L, Auvray M, Dautruche A, Vano YA, Thibault C, Joly F, Brunereau L, Gomez-Roca C, Chevreau C, Elaidi R, Oudard S.

Clin Genitourin Cancer. 2017 Jun;15(3):350-355. doi: 10.1016/j.clgc.2017.01.022. Epub 2017 Feb 1.

PMID:
28216276
19.

Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.

Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, Sanchez-Salas R, Ingels A, Oudard S, Moatti A, Buttard B, Bourass S, Germain C, Cathelineau X, Fridman WH, Sautès-Fridman C.

Clin Cancer Res. 2017 Aug 1;23(15):4416-4428. doi: 10.1158/1078-0432.CCR-16-2848. Epub 2017 Feb 17.

20.

Immunothérapie dans les cancers de la prostate.

Oudard S, Thibault C, Angelergues A, Tartour E, Timsit MO, Mejean A, Michel C, Vano Y.

Bull Cancer. 2016 Nov;103 Suppl 1:S144-S150. doi: 10.1016/S0007-4551(16)30372-1. French.

PMID:
28057178
21.

Sunitinib in kidney cancer: 10 years of experience and development.

Nassif E, Thibault C, Vano Y, Fournier L, Mauge L, Verkarre V, Timsit MO, Mejean A, Tartour E, Oudard S.

Expert Rev Anticancer Ther. 2017 Feb;17(2):129-142. doi: 10.1080/14737140.2017.1272415. Epub 2016 Dec 27. Review.

PMID:
27967249
22.

Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals.

Tlemsani C, Mir O, Psimaras D, Vano YA, Ducreux M, Escudier B, Rousseau B, Loirat D, Ceccaldi B, André T, Goldwasser F, Ricard D.

Eur J Cancer. 2016 Oct;66:75-82. doi: 10.1016/j.ejca.2016.07.008. Epub 2016 Aug 15.

PMID:
27529757
23.

Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.

Oudard S, Joly F, Geoffrois L, Laguerre B, Houede N, Barthelemy P, Gross-Goupil M, Vano Y, Lucidarme O, Bidault F, Kelkouli N, Slimane K, Escudier B.

Clin Genitourin Cancer. 2016 Dec;14(6):e595-e607. doi: 10.1016/j.clgc.2016.04.019. Epub 2016 May 2.

PMID:
27283478
24.

Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC).

Becht E, Giraldo NA, Beuselinck B, Job S, Marisa L, Vano Y, Oudard S, Zucman-Rossi J, Laurent-Puig P, Sautès-Fridman C, de Reyniès A, Fridman WH.

Oncoimmunology. 2015 Aug 7;4(12):e1049804. eCollection 2015 Dec.

25.

The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma.

Oudard S, Vano Y.

Curr Opin Urol. 2015 Sep;25(5):402-10. doi: 10.1097/MOU.0000000000000206. Review.

PMID:
26148068
26.

The immune response in cancer: from immunology to pathology to immunotherapy.

Giraldo NA, Becht E, Vano Y, Sautès-Fridman C, Fridman WH.

Virchows Arch. 2015 Aug;467(2):127-35. doi: 10.1007/s00428-015-1787-7. Epub 2015 Jun 16. Review.

PMID:
26077464
27.

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.

Giraldo NA, Becht E, Pagès F, Skliris G, Verkarre V, Vano Y, Mejean A, Saint-Aubert N, Lacroix L, Natario I, Lupo A, Alifano M, Damotte D, Cazes A, Triebel F, Freeman GJ, Dieu-Nosjean MC, Oudard S, Fridman WH, Sautès-Fridman C.

Clin Cancer Res. 2015 Jul 1;21(13):3031-40. doi: 10.1158/1078-0432.CCR-14-2926. Epub 2015 Feb 16.

28.

Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.

Elaidi R, Harbaoui A, Beuselinck B, Eymard JC, Bamias A, De Guillebon E, Porta C, Vano Y, Linassier C, Debruyne PR, Gross-Goupil M, Ravaud A, Aitelhaj M, Marret G, Oudard S.

Ann Oncol. 2015 Feb;26(2):378-85. doi: 10.1093/annonc/mdu552. Epub 2014 Dec 1.

PMID:
25467013
29.

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

Oudard S, Culine S, Vano Y, Goldwasser F, Théodore C, Nguyen T, Voog E, Banu E, Vieillefond A, Priou F, Deplanque G, Gravis G, Ravaud A, Vannetzel JM, Machiels JP, Muracciole X, Pichon MF, Bay JO, Elaidi R, Teghom C, Radvanyi F, Beuzeboc P.

Eur J Cancer. 2015 Jan;51(1):45-54. doi: 10.1016/j.ejca.2014.10.009. Epub 2014 Nov 15.

PMID:
25459391
30.

Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.

Vano YA, Tartour E, Fournier LS, Beuselinck B, Mejean A, Oudard S.

Expert Rev Anticancer Ther. 2014 May;14(5):523-42. doi: 10.1586/14737140.2014.882773. Epub 2014 Mar 18. Review.

PMID:
24640949
31.

Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.

Beuselinck B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-Rossi J, Debruyne PR, Van Poppel H, Joniau S, Lerut E, Strijbos M, Dumez H, Paridaens R, Van Calster B, Schöffski P.

BJU Int. 2014 Jul;114(1):81-9. doi: 10.1111/bju.12494. Epub 2014 Jan 15.

32.

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series.

Rodrigues MJ, Peron J, Frénel JS, Vano YA, Wassermann J, Debled M, Picaud F, Albiges L, Vincent-Salomon A, Cottu PH.

Ann Oncol. 2013 Apr;24(4):916-24. doi: 10.1093/annonc/mds536. Epub 2012 Oct 26.

PMID:
23104720
33.

GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.

Spano JP, Vano Y, Vignot S, De La Motte Rouge T, Hassani L, Mouawad R, Menegaux F, Khayat D, Leenhardt L.

Med Oncol. 2012 Sep;29(3):1421-8. doi: 10.1007/s12032-011-0070-2. Epub 2011 Sep 25.

PMID:
21947747
34.

[Epidemiological link between eating habits and cancer: the example of colorectal cancer].

Vano YA, Rodrigues MJ, Schneider SM.

Bull Cancer. 2009 Jun;96(6):647-58. doi: 10.1684/bdc.2009.0874. Review. French.

Supplemental Content

Support Center